Market Capitalization (Millions $) |
75 |
Shares
Outstanding (Millions) |
18 |
Employees |
- |
Revenues (TTM) (Millions $) |
2 |
Net Income (TTM) (Millions $) |
-47 |
Cash Flow (TTM) (Millions $) |
27 |
Capital Exp. (TTM) (Millions $) |
0 |
Delcath Systems Inc
Delcath Systems Inc is a medical technology company that specializes in the development and commercialization of products and therapies for the treatment of cancer. The company's main focus is on precision-targeted, whole organ chemotherapy, known as the Delcath Hepatic CHEMOSAT Delivery System. This system is designed to deliver high-dose chemotherapy directly to the liver while minimizing exposure to the rest of the body, thereby reducing toxic side effects. Delcath Systems Inc aims to improve patient outcomes and provide physicians with innovative treatment options for liver metastases.
Company Address: 1633 Broadway New York 10019 NY
Company Phone Number: 489-2100 Stock Exchange / Ticker: NASDAQ DCTH
DCTH is expected to report next financial results on March 26, 2024. |
|
|